Celebrating 30 years of BioWorld

BioWorld™ has built an enduring relationship with everyone in the drug development and medical technology sectors. As we celebrate our 30th anniversary, we reflect on how the publication has changed over the years to accommodate shifts in media consumption and industry needs.   BioWorld has built an enduring relationship with everyone in the drug development […]

The European MDR: Impetus, Impacts, And Current Status

In May 2017, the European Medical Devices Regulation (MDR), approved by the European Council and European Parliament earlier that year, came into force, setting the stage for its application. Initially set as May 26, 2020, the MDR DoA was postponed one year in April 2020 in response to the COVID-19 pandemic. The regulation was introduced […]

COVID-19 Brings Seismic Shifts to Future Healthcare Delivery

The coronavirus pandemic is rapidly reshaping the way patients access care and the strategy of healthcare providers treating those patients. The situation echoes other recent national seismic shifts —the Great Recession and Affordable Care Act—that drove changes like increased healthcare consolidation and value-based care. Patients, many reluctant to seek care at medical facilities or even […]

COVID-19 Pandemic: Current Status and Medtech Impact

The ongoing coronavirus disease (COVID-19) pandemic was caused by a novel coronavirus (SARS-CoV-2) – which leads to an unusual viral pneumonia in patients – that was first identified in Wuhan, China in December 2019. It has since then spread to 205 countries and territories, with the strongest impact observed in the US, China, Western Europe, Iran, and […]

The COVID-19 pandemic: European regulators respond

The COVID-19 pandemic is spreading around the world with, as of this writing, more than one million cases globally and more than 500,000 cases in Europe alone. Here we summarize how The European Medicines Agency (EMA) as well as the European Commission (EC), the Heads of Medicines Agency (HMA) and the European Center for Disease […]

Impact of COVID-19: 4 challenges life science companies face

The COVID-19 pandemic has placed healthcare systems across the world under enormous strain, while life sciences companies scramble to do their part in addressing the disease. Medtech companies are working harder to develop and deliver more reliable diagnostic tests or meet the soaring need for ventilators and personal protective equipment. Biopharmas are racing against time […]

5 Macrotrends Changing the Way Medtech Does Business

In recent years, global medtech markets have been dominated by some key overarching drivers: growing efforts to reduce healthcare costs, an increasing interest in value-based care – reflected by heightened emphasis on patient safety and efficacious treatment approaches – and expanded opposition to barriers to entry, whether from technical trade barriers or a lack of […]

9 steps for modernizing your medtech account segmentation strategy

The complexity of the medtech purchasing ecosystem has rendered a traditional approach ineffective. Here’s how to get up to speed. Account segmentation and targeting used to be a pretty straightforward business: Examine CMS claims data to get a read on volumes being performed and compare against historic sales into the account to prioritize sales rep […]